NCT00439556View on ClinicalTrials.gov

Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 13, 2007

Primary Completion Date

June 7, 2018

Study Completion Date

June 7, 2018

Conditions
CD20 PositiveHematopoietic and Lymphoid Cell NeoplasmLymphocytic NeoplasmLymphoma
Interventions
PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo allogeneic hematopoietic stem cell transplantation

BIOLOGICAL

Anti-Thymocyte Globulin

Given IV

DRUG

Bortezomib

Given IV

DRUG

Carmustine

Given IV

DRUG

Cytarabine

Given IV

DRUG

Etoposide

Given IV

BIOLOGICAL

Filgrastim

Given SC

DRUG

Melphalan

Given IV

DRUG

Methotrexate

Given IV

BIOLOGICAL

Rituximab

Given IV

DRUG

Tacrolimus

Given IV and PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00439556 - Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant | Biotech Hunter | Biotech Hunter